Inovio Pharmaceuticals, INC Form 4 insider transactions

Director Wendy Yarno reports the vesting and subsequent disposal of restricted stock units into common stock of Inovio Pharmaceuticals.

CFO of Inovio Pharmaceuticals, Peter Kies, reports the acquisition of restricted stock units and stock options.

Director Roger Dansey reports the vesting and subsequent disposal of restricted stock units into common stock of Inovio Pharmaceuticals.

Chief Medical Officer of Inovio Pharmaceuticals, Michael John Sumner, reports acquisition of stock options and restricted stock units.

Director David B. Weiner reports the vesting of restricted stock units into Inovio Pharmaceuticals common stock.

Michael John Sumner, Chief Medical Officer of Inovio Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.

Jacqueline E. Shea, CEO of Inovio Pharmaceuticals, reports the vesting and settlement of restricted stock units, along with associated tax withholding.

CFO of Inovio Pharmaceuticals, Peter Kies, reports the vesting and disposal of restricted stock units to cover tax obligations.

Laurent Humeau, Chief Scientific Officer of Inovio Pharmaceuticals, reports the vesting and disposal of restricted stock units to cover tax obligations.

CEO Jacqueline Shea reports the vesting of restricted stock units and subsequent tax withholding by Inovio Pharmaceuticals.

Laurent Humeau, Chief Scientific Officer of Inovio Pharmaceuticals, reports the vesting and disposal of restricted stock units and the acquisition of stock options.

Chief Medical Officer Michael John Sumner reports the vesting and disposal of restricted stock units and the grant of stock options in Inovio Pharmaceuticals.

CEO Jacqueline Elizabeth Shea reports acquisition and disposal of Inovio Pharmaceuticals stock and derivative securities related to vesting of restricted stock units and options.

CFO of Inovio Pharmaceuticals, Peter Kies, reports the vesting and disposal of restricted stock units and the acquisition of stock options.

Director David B. Weiner reports the vesting and settlement of restricted stock units into Inovio Pharmaceuticals common stock.

Inovio Pharmaceuticals' Chief Medical Officer, Michael John Sumner, acquired stock options and restricted stock units on December 18, 2024, according to a recent SEC filing.

Chief Medical Officer Michael John Sumner reports the vesting and acquisition of Inovio Pharmaceuticals' common stock and restricted stock units.

Director Lota S. Zoth reports the acquisition of stock options and restricted stock units in Inovio Pharmaceuticals.

Director Jay Shepard reports the acquisition of stock options and restricted stock units in Inovio Pharmaceuticals, granted under the 2023 Omnibus Incentive Plan.

Director Ann Calby Miller reports acquisition of stock options and restricted stock units in Inovio Pharmaceuticals.

Director David B. Weiner reports the acquisition of stock options and restricted stock units in Inovio Pharmaceuticals, Inc. on May 21, 2024.

Director Wendy Yarno reports the acquisition of stock options and restricted stock units in Inovio Pharmaceuticals.

Director Simon X. Benito reports the acquisition of stock options and restricted stock units in Inovio Pharmaceuticals.

Director Roger D. Dansey reports the acquisition of stock options and restricted stock units in Inovio Pharmaceuticals.

Director Ann Calby Miller reports the vesting and acquisition of 2,166 shares of Inovio Pharmaceuticals common stock on May 15, 2024, related to restricted stock units.

Director Simon X. Benito reports the vesting and acquisition of 2,166 shares of Inovio Pharmaceuticals common stock on May 15, 2024, related to restricted stock units.

Director Jay Shepard reports vesting of restricted stock units convertible to common stock in Inovio Pharmaceuticals.

CFO Peter Kies reports the vesting of restricted stock units and subsequent tax withholding by Inovio Pharmaceuticals.

Laurent Humeau, Chief Scientific Officer of Inovio Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.

Chief Medical Officer Michael John Sumner reports the vesting of restricted stock units in Inovio Pharmaceuticals.